Dicerna Pharmaceuticals Inc (DRNA) Stock
DRNA is no longer traded. Dicerna Pharmaceuticals was acquired by Novo Nordisk (NVO) on December 28, 2021.
Each DRNA share was exchanged for $38.25 in cash. Prices on this page are historical; the last trade was December 27, 2021 at $38.22.
See Novo Nordisk (NVO) stock →Dicerna Pharmaceuticals stock price history
DRNA final trading statistics
- Final close
- $38.22
- Final trading day
- Dec 27, 2021
- Market cap at delisting
- $2.98B
- Shares outstanding
- 77.91M
- Final 52-week range
- $19.06 – $40.14
- Avg. volume (final 3 mo.)
- 2,949,892
- All-time high (split-adj.)
- $46.00 · Jan 2014
- All-time low (split-adj.)
- $2.45 · Feb 2017
- Return since IPO
- -16.9%
- Beta
- 0.79
- Book value / share
- $1.38
- Price / book
- 27.64
Dicerna Pharmaceuticals annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2020 | $164.31M | -$112.7M | -$1.52 |
| FY2019 | $23.90M | -$120.5M | -$1.76 |
| FY2018 | $6.18M | -$88.9M | -$1.62 |
| FY2017 | $2.28M | -$60.0M | -$3.65 |
| FY2016 | $295.0K | -$59.5M | -$2.87 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Dicerna Pharmaceuticals Inc
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.
Dicerna Pharmaceuticals stock FAQ
What happened to Dicerna Pharmaceuticals stock?
Dicerna Pharmaceuticals was acquired by Novo Nordisk (NVO) on December 28, 2021. Shareholders received $38.25 in cash for each share. DRNA stock stopped trading on the Nasdaq, with a final close of $38.22 on December 27, 2021.
What did Dicerna Pharmaceuticals shareholders receive?
Each DRNA share was converted into $38.25 in cash. The deal was valued at about $3.3 billion.
Is DRNA stock still trading?
No. DRNA was delisted from the Nasdaq on December 28, 2021 and no longer trades on a U.S. exchange.
What was the last price of DRNA stock?
DRNA closed at $38.22 on its final trading day, December 27, 2021, for a market value of about $2.98B.
What were Dicerna Pharmaceuticals's revenue and earnings in its last full fiscal year?
Dicerna Pharmaceuticals reported revenue of $164.31M and net income of -$112.7M in fiscal 2020, its last full year as a public company.
When did Dicerna Pharmaceuticals go public?
Dicerna Pharmaceuticals Inc stock began trading on January 30, 2014.